LivaNova PLC (LivaNova) is engaged in the designing, development, manufacturing, and distribution of therapeutic solutions in the areas of cardiac surgery and neuromodulation. The company offers its solutions to patients, healthcare professionals, and healthcare systems. LivaNova caters to clients across the world in over 100 countries. Its major target markets include the US, Japan, and Europe. It markets and sells its products through direct sales representatives in the US and a combination of direct sales representatives and independent distributors outside the US. LivaNova maintains 31 primary administrative offices in 21 countries.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

LivaNova's research and development (R&D) initiatives focus on advancing its core portfolio and pipeline initiatives, particularly in the areas of Epilepsy and Cardiopulmonary. In Epilepsy, the company is working on a next-generation system with cloud connectivity and driving clinical evidence initiatives for VNS Therapy. In Cardiopulmonary, efforts are directed towards developing a next-generation oxygenator and enhancing capabilities for Essenz. Additionally, the company is investing in two pipeline initiatives, DTD and OSA, with the RECOVER study and OSPREY trial targeting medical conditions with high unmet needs. LivaNova also focused on technological enhancements, new uses for existing products, and less invasive technologies to address unmet patient needs. In FY2024, the company spent US$182.5 million on R&D, which as a percentage of revenue, stood at 14.6% and declined 5.8% YoY. As of December 2024, the company operated research facilities in the US, Italy, Germany, Australia, and Brazil.